PartnershipJun 17, 2026, 12:42 PM
AbCellera & Jazz Pharma Partner for Cancer Antibodies; $56M Upfront
AI Summary
AbCellera Biologics Inc. announced a preclinical research collaboration, option, and license agreement with Jazz Pharmaceuticals. The partnership aims to discover and develop next-generation T-cell engaging multispecific antibodies for various gastrointestinal cancers and other solid tumors, leveraging AbCellera's antibody discovery engine. AbCellera will receive $56 million in upfront payments for the initial two programs, with an additional $28 million upon starting a third program. The agreement also includes potential option fees and milestone payments of up to $792 million per program, plus tiered royalties on net sales.
Key Highlights
- AbCellera and Jazz Pharmaceuticals formed a preclinical research collaboration.
- The partnership focuses on T-cell engaging multispecific antibodies for GI and solid tumors.
- AbCellera receives $56 million in upfront payments for two initial programs.
- An additional $28 million is due upon initiation of a third program.
- Potential milestone payments could reach up to $792 million per program.
- AbCellera is eligible for tiered royalties on net sales, from mid-single digits to low double-digits.
- Jazz Pharmaceuticals holds the exclusive option to develop and commercialize resulting programs.
Price Impact
More from ABCL